2 weeks Ago By ABMN Staff
StockNews.com upgraded shares of Nevro ( NYSE:NVRO – Free Report ) from a sell rating to a hold rating in a report released on Monday morning. Several other equities analysts have also commented on the stock.
Wolfe Research upgraded shares of Nevro from an underperform rating to a peer perform rating in a research report on Thursday, August 8th. Piper Sandler decreased their price objective on shares of Nevro from $12.00 to $7.
00 and set an underweight rating for the company in a report on Wednesday, August 7th. JPMorgan Chase & Co. lowered shares of Nevro from a neutral rating to an underweight rating in a report on Wednesday, August 7th.
Morgan Stanley decreased their price objective on shares of Nevro from $14.00 to $9.00 and set an equal weight rating for the company in a report on Monday, July 15th.
Finally, JMP Securities lowered shares of Nevro from an outperform rating to a market perform rating in a report on Wednesday, August 7th. Three research analysts have rated the stock with a sell rating and twelve have given a hold rating to the company. According to MarketBeat.
com, the stock presently has an average rating of Hold and an average target price of $10.63. Read Our Latest Analysis on Nevro Nevro Stock Performance Nevro ( NYSE:NVRO – Get Free Report ) last posted its quarterly earnings data on Tuesday, August 6th.
The medical equipment provider reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.
10. Nevro had a negative net margin of 18.17% and a negative return on equity of 24.
89%. The business had revenue of $104.16 million for the quarter, compared to analyst estimates of $107.
11 million. During the same quarter in the previous year, the firm posted ($0.69) earnings per share.
Nevro’s quarterly revenue was down 4.3% on a year-over-year basis. On average, equities research analysts expect that Nevro will post -2.
6 earnings per share for the current fiscal year. Institutional Trading of Nevro Large investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC boosted its holdings in shares of Nevro by 1,788.
8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 6,932 shares of the medical equipment provider’s stock valued at $58,000 after acquiring an additional 6,565 shares during the last quarter. Canada Pension Plan Investment Board boosted its holdings in shares of Nevro by 345.
8% in the 2nd quarter. Canada Pension Plan Investment Board now owns 10,700 shares of the medical equipment provider’s stock valued at $90,000 after acquiring an additional 8,300 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its holdings in shares of Nevro by 14.
1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 11,578 shares of the medical equipment provider’s stock valued at $167,000 after acquiring an additional 1,430 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of Nevro by 84.
6% in the 2nd quarter. XTX Topco Ltd now owns 24,711 shares of the medical equipment provider’s stock valued at $208,000 after acquiring an additional 11,323 shares during the last quarter. Finally, Oppenheimer Asset Management Inc.
boosted its holdings in shares of Nevro by 45.3% in the 1st quarter. Oppenheimer Asset Management Inc.
now owns 30,727 shares of the medical equipment provider’s stock valued at $444,000 after acquiring an additional 9,586 shares during the last quarter. Hedge funds and other institutional investors own 95.52% of the company’s stock.
About Nevro ( Get Free Report ) Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.
Recommended Stories Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter ..
